The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Casgevy is the first drug to be licensed based on CRISPR, a gene-editing technique for which its discoverers won a Nobel Prize in 2020. It has also been submitted for approval in the US and EU ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

The Food and Drug Administration approval in December 2023 of the first CRISPR therapeutic, Casgevy to treat sickle cell, came 11 years after the discovery of the revolutionary gene-editing technology ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

In a shift away from GMOS, aka genetically modified organisms, important research is continuing in gene editing, sometimes ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors. If you select quality ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

NEW YORK – Intellia Therapeutics on Wednesday said it has dosed the first hereditary angioedema patient within the Phase III HAELO trial of the investigational in vivo CRISPR-based gene-editing ...